Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Intravenously transplanted mesenchymal stromal cells: a new endocrine reservoir for cardioprotection

Fig. 6

The MiR-181a-5p inhibitor weakens the cardioprotective ability of MSCs. A. Experimental design of in vitro study with the miR181a-5p inhibitor. B. Statistics of miR-181a-5p expression in cardiomyocytes exposed to PBS (Control), InhibitorNC, or InhibitormiR−181a−5p (n = 3). **P < 0.01 vs Control. #P < 0.05 vs InhibitorNC. Data were analyzed by one-way ANOVA followed by Bonferroni post hoc test, unless specifically indicated. C. Representative immunofluorescence images of antibody to α-actinin (Red) and GRP78 (green) binding to cardiomyocytes exposed to Dox/MSC-EVs-InhibitorNC, or Dox/MSC-EVs-InhibitormiR−181a−5p. Scale bar, 50 μm. D. Statistics of GRP78 expression in cardiomyocytes exposed to Dox/MSC-EVs-InhibitorNC, or Dox/MSC-EVs-InhibitormiR−181a−5p (n = 3). **P < 0.01 vs Dox/MSC-EVs-InhibitorNC. Data were analyzed by unpaired two-tailed Student’s t test. E. Western Blotting and quantitative protein expression showing stress-induced apoptosis in cardiomyocytes exposed to PBS (Control), Dox/PBS, Dox/EVs-InhibitorNC, or Dox/EVs-InhibitormiR−181a−5p, (n = 5). **P < 0.01, ***P < 0.001, ****P < 0.0001 vs Control, #P < 0.05 vs Dox/PBS, &&P < 0.01, &&&P < 0.001 vs Dox/MSC-EVs-InhibitorNC. Data were analyzed by one-way ANOVA followed by Bonferroni post hoc test, unless specifically indicated. G. Representative bright-field images of cardiomyocytes exposed to Dox/MSC-EVs-InhibitorNC, or Dox/MSC-EVs-InhibitormiR−181a−5p. Scale bar, 100 μm. H. Representative Annexin V-FITC/PI FACS staining and quantitative apoptotic proportion of cardiomyocytes exposed to Dox/MSC-EVs-InhibitorNC, or Dox/MSC-EVs-InhibitormiR−181a−5p (n = 3). **P < 0.01 vs Dox/MSC-EVs-InhibitorNC. Data were analyzed by unpaired two-tailed Student’s t test

Back to article page